Hsbc Holdings PLC Protalix Bio Therapeutics, Inc. Transaction History
Hsbc Holdings PLC
- $145 Billion
- Q1 2024
A detailed history of Hsbc Holdings PLC transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 46,680 shares of PLX stock, worth $49,014. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,680
Previous 40,066
16.51%
Holding current value
$49,014
Previous $71,000
18.31%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding PLX
# of Institutions
66Shares Held
9.27MCall Options Held
40.6KPut Options Held
10.1K-
Black Rock Inc. New York, NY3.31MShares$3.48 Million0.0% of portfolio
-
State Street Corp Boston, MA827KShares$867,9100.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny825KShares$865,9350.0% of portfolio
-
Geode Capital Management, LLC Boston, MA754KShares$791,8150.0% of portfolio
-
Gsa Capital Partners LLP London, X0494KShares$518,2490.05% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $52.2M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...